Oct 30, 2026
Amrize Stock: What Investors Need to Know
amrize stock explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Publisher
Porter & Co.
Promos from Porter & Co., vetted by NewsletterVetter.
Known editors: Various
Vets published: 80
Oct 30, 2026
Dedollarization: What You Need to Know
dedollarization explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
EQT Stock: What Investors Need to Know
eqt stock explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Mineral Royalty: What You Need to Know
mineral royalty explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Petrodollar: What You Need to Know
petrodollar explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Sitio Royalties: What You Need to Know
sitio royalties explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Versamet Royalties Stock: What Investors Need to Know
versamet royalties stock explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Vicor Stock: What Investors Need to Know
vicor stock explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Viper Energy Stock: What Investors Need to Know
viper energy stock explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 30, 2026
Waterbridge Infrastructure Stock: What Investors Need to Know
waterbridge infrastructure stock explained: what it means for investors and how Porter Stansberry's research at Porter & Co approaches this opportunity.
Oct 28, 2026
What Porter & Co Won't Tell You About Trump's Dollar Reset (a.k.a. 'Trump's New Dollar' / 'The Dollar Switch Has Begun')
VICR, VMET, EQT, VNOM, WBI and AMRZ are the stocks behind Porter & Co's 'Trump's Dollar Reset' pitch. We checked the math — here's what the promo won't tell you.
Oct 27, 2026
What Porter & Co. Won't Tell You About Your Own 'Perpetual Money Machine'
We identified CB, KNSL, WRB behind Porter & Co.'s Your Own 'Perpetual Money Machine' promo and checked the math. Here's what the pitch won't tell you.
Sep 27, 2026
Porter & Co.'s 'Artificial Illusion' — The Three 'Forever Stocks' Behind the 'AI Railroad' Pitch
Porter Stansberry's 'Artificial Illusion' pitch named PayPal, Ulta Beauty, and Deere 'AI Railroad' plays. Three years on: one big winner, one modest, one loser.
Sep 27, 2026
Braintree Payments: What Investors Need to Know
Braintree is the hidden B2B processor inside PayPal (PYPL), handling hundreds of billions in volume. What it does and why Stansberry flags it.
Sep 27, 2026
Deere Stock: What Investors Need to Know
Deere (DE) is the 'Apple of Agriculture' in Porter's Artificial Illusion pitch, and it's the one pick that actually delivered, up about 90%.
Sep 27, 2026
Fintech Stocks: What Investors Need to Know
The 'AI Railroad' idea treats payment rails as infrastructure. Why fintech stocks are not the same thing as AI beneficiaries.
Sep 27, 2026
Forever Stocks: What Investors Need to Know
Porter's 'forever stocks' promise 40 quarters of growth and 15% compounding. What the label actually means, and where it oversold.
Sep 27, 2026
PayPal Competitors: What You Need to Know
Adyen, Marqeta, Block, and Stripe compete on the payment rails where PayPal's Braintree lives. The competitive set in plain terms.
Sep 27, 2026
PayPal Stock: What You Need to Know
PayPal (PYPL) was teased as a trillion-dollar 'forever stock' at $57.97. Three years later it's below that. What the scorecard shows.
Sep 27, 2026
PayPal Venmo: What You Need to Know
Venmo is PayPal's (PYPL) consumer P2P brand, a different business from Braintree's B2B rails. What each contributes to the valuation.
Sep 27, 2026
Precision Farming: What You Need to Know
The 'Apple of Agriculture' pitch leans on cameras and AI that cut chemical use up to 80% on a Deere (DE) tractor. How it actually works.
Sep 27, 2026
Ulta Beauty Stock: What Investors Need to Know
Ulta Beauty (ULTA) was teased as 'the prettiest stock on Wall Street.' The 15% compounding claim versus the 9% it actually delivered.
Sep 24, 2026
Porter & Co.'s 'Ignition Point' — The Five Gene-Silencing Stocks Behind the Lp(a) Boom
Porter Stansberry's Ignition Point hides four gene-silencing picks plus a bonus 'NVIDIA of Medicine.' We decode all five and test whether the Lp(a) story holds.
Sep 24, 2026
Alnylam Stock: Porter's RNAi 'Anchor' Pick, Explained
Alnylam (ALNY) is the 'Anchor' in Porter & Co.'s Ignition Point biotech pitch. We unpack the RNAi pioneer's patents, revenue, and valuation risks.
Sep 24, 2026
Amgen Stock and the Lp(a) Race: What to Know
Amgen's olpasiran is the Lp(a) drug to watch, and it sits outside Porter & Co.'s Ignition Point picks. Here's what that means for Amgen stock.
Sep 24, 2026
Arrowhead Pharmaceuticals Stock: Porter's 'Challenger' Pick
Arrowhead (ARWR) is the 'Challenger' in Porter & Co.'s Ignition Point pitch. We break down the TRiM platform, the royalty sale, and the risks.
Sep 24, 2026
Best Biotech Stocks: Porter's Barbell Framework, Explained
Porter & Co.'s Ignition Point pitch pairs royalty 'tollbooth' names with speculative gene-silencing bets. Here's how the barbell is built.
Sep 24, 2026
Biotech Stocks to Buy: The 'Own the Sector' Argument
Porter & Co.'s own pitch concedes most biotech alpha comes from owning the sector during a boom. We unpack that idea for stock pickers.
Sep 24, 2026
CRISPR Stocks vs Gene-Silencing Stocks: Know the Difference
CRISPR edits genes; RNA interference silences them. Porter & Co.'s Ignition Point is a silencing pitch, not an editing one. Here's the difference.
Sep 24, 2026
Dicerna Pharmaceuticals: The Lilly Deal Behind Lepodisiran
Dicerna was acquired by Eli Lilly, and its RNAi platform produced the Lp(a) drug lepodisiran. Here's what investors should understand.
Sep 24, 2026
Eli Lilly Stock: Is It Really 'The NVIDIA of Medicine'?
Porter & Co.'s Ignition Point bonus pick calls Eli Lilly (LLY) 'the NVIDIA of medicine.' We test that comparison against the actual numbers.
Sep 24, 2026
Gene Silencing: The Science Behind the Ignition Point Pitch
Gene silencing shuts down the genes that make disease-causing proteins. Here's how antisense and RNAi drugs work, in plain English.
Sep 24, 2026
Gene Therapy Stocks vs Gene Silencing: A Key Distinction
Gene therapy replaces genes; gene silencing turns them off. The two biotech categories carry very different risk profiles. Here's the map.
Sep 24, 2026
Halozyme Stock: The Tollbooth on Injectable Biologics
Halozyme's ENHANZE tech earns royalties on major injectable drugs. We explain the business model behind this biotech 'tollbooth.'
Sep 24, 2026
Ionis Pharmaceuticals Stock: The Antisense Pioneer
Ionis licensed the antisense drug behind Novartis's Lp(a) trial. Here's how the antisense pioneer fits the gene-silencing story.
Sep 24, 2026
Ligand Pharmaceuticals Stock: A Royalty Business Model
Ligand collects royalties on drugs it helped develop. We explain the royalty model behind this biotech 'tollbooth' stock.
Sep 24, 2026
Lipoprotein(a): The Cholesterol Statins Can't Lower
Lp(a) is a genetically driven form of cholesterol that diet and statins barely move. Here's the biology behind the Ignition Point pitch.
Sep 24, 2026
Lipoprotein(a) Drugs: The Race to Lower Lp(a)
Pelacarsen, olpasiran, lepodisiran, and zerlasiran are racing to lower Lp(a). Here's how the four contenders stack up behind the Ignition Point pitch.
Sep 24, 2026
The Lp(a) Drug Endpoint Problem: Biomarker vs Outcome
Novartis's pelacarsen lowered Lp(a) but failed to cut cardiovascular events. That biomarker-versus-outcome gap matters for every Lp(a) drug.
Sep 24, 2026
Novartis Stock: Porter's 'Ballast' Pick and the Failed Trial
Porter & Co. calls Novartis (NVS) the 'Ballast' of its Ignition Point pitch. But the pelacarsen trial it touts already failed its endpoint.
Sep 24, 2026
Pharmaceutical Stocks: Diversified Giants vs Single-Asset Bets
The Ignition Point pitch spans a $269B pharma giant and a $764M microcap. Here's how risk differs across pharmaceutical stocks.
Sep 24, 2026
RNA Interference: The Drug Class Behind Gene Silencing
RNA interference lets drugs silence specific genes, and it won a Nobel Prize. Here's how RNAi works and why it matters to biotech.
Sep 24, 2026
RNA Interference Stocks: The Investment Universe
Alnylam, Arrowhead, and Silence Therapeutics are the pure-play RNAi names. Here's how to think about RNA interference stocks.
Sep 24, 2026
Royalty Pharma Stock: The Tollbooth Aggregator
Royalty Pharma buys royalty streams on approved drugs, including Arrowhead's olpasiran royalty. Here's how the aggregator works.
Sep 24, 2026
Silence Therapeutics Stock: Porter's 'Lightning Strike' Pick
Silence Therapeutics (SLN) is the 'Lightning Strike' in Porter & Co.'s pitch, trading near $11. The '99%' claim is a biomarker, not an outcome.
Sep 24, 2026
XOMA Royalty Stock: The Small-Cap Royalty Aggregator
XOMA Royalty collects royalties on licensed drug programs. We explain the small-cap royalty model behind this biotech 'tollbooth.'
Sep 1, 2026
Best LNG Stocks: What Investors Need to Know
The best LNG stocks benefit from the same export dynamics Porter Stansberry highlights in his Boston Blackout thesis. Here are the names to know and the
Sep 1, 2026
Best Natural Gas Stocks: What Investors Need to Know
The best natural gas stocks reflect the same LNG export and demand dynamics that drive Porter Stansberry's Boston Blackout thesis.
Sep 1, 2026
Cheniere Energy Stock: What Investors Need to Know
Cheniere Energy (LNG) is the established benchmark in US LNG exports, and the contrast case to Porter Stansberry's Venture Global pick.
Sep 1, 2026
LNG Companies: What Investors Need to Know
LNG companies are at the center of Porter Stansberry's Boston Blackout thesis. Here is how the LNG export industry works and which companies lead the space.
Sep 1, 2026
LNG Liquefaction: What You Need to Know
LNG liquefaction is the critical step that turns natural gas into a shippable liquid, and Porter Stansberry's Boston Blackout thesis depends on it.
Sep 1, 2026
LNG Stocks: What Investors Need to Know
LNG stocks are riding the natural gas export wave that Porter Stansberry's Boston Blackout pitch highlights. Here is a look at the publicly traded LNG
Sep 1, 2026
Natural Gas ETF: What Investors Need to Know
Natural gas ETFs offer direct exposure to gas prices, but the contango problem makes them trickier than they look. Here is what Porter Stansberry's Boston
Sep 1, 2026
Natural Gas Futures: What Investors Need to Know
Natural gas futures are the purest way to bet on gas prices, but they carry risks most equity investors underestimate. Here is what Porter Stansberry's
Sep 1, 2026
Natural Gas Prices Investing: What You Need to Know
Natural gas prices are at the center of Porter Stansberry's Boston Blackout thesis. Here is what drives US natural gas prices and how investors can think
Sep 1, 2026
Natural Gas Stocks: What Investors Need to Know
Natural gas stocks are the equity play on the demand surge Porter Stansberry outlines in his Boston Blackout thesis. Here are the categories of natural gas
Sep 1, 2026
Natural Gas Stocks to Buy: What Investors Need to Know
The natural gas stocks to buy depend on how you want exposure to the demand surge Porter Stansberry highlights in his Boston Blackout thesis.
Sep 1, 2026
Venture Global LNG: What Investors Need to Know
Venture Global LNG is the company behind Porter Stansberry's Boston Blackout pick. Here is how its liquefaction terminals work, its competitive position,
Sep 1, 2026
Venture Global Stock: What Investors Need to Know
Venture Global (VG) is the LNG export name Porter Stansberry teased in his Boston Blackout pitch. Here is what the company does, how its numbers stack up,
Aug 31, 2026
Porter & Co.'s 'Three Boston Blackout Winners' — The LNG Exporter Behind the Winter Gas Shock
Porter Stansberry's winter blackout pitch hides three picks behind a 50 Bcf/d gas-demand surge. We reveal the one fresh name, Venture Global, and test the math.
Aug 31, 2026
Porter & Co.'s 'Hunting for 100-Baggers' — The Three Stocks Behind Emmet Savage's 10,000% Claims
We decode the Nova and Prophet pitch and reveal the three stocks behind Emmet Savage's 100-bagger claims: TransMedics, Lemonade, and Rocket Lab.
Aug 24, 2026
Porter & Co.'s 'Final Displacement' — The Nine Stocks Behind the AI Labor Fear Pitch
Porter Stansberry's $199 'Final Displacement' bundle names nine AI-chokepoint stocks, from ASML and Arm to a 'King of Coal.' We walk through every pick and
Aug 14, 2026
Porter & Co.'s 'Royalty Riches' — The Five Capital-Light Stocks Behind the 'Mini-Buffett' Pitch
Porter Stansberry's 'Royalty Riches' names five royalty stocks as the most capital-efficient businesses on earth. We reveal all five tickers and test each
Aug 14, 2026
Barrick Gold: What You Need to Know
Barrick Gold (GOLD) is a miner, not a royalty company. Here's why it shows up in Porter Stansberry's Royalty Riches story anyway.
Aug 14, 2026
Best Royalty Stocks: What You Need to Know
Porter Stansberry's Royalty Riches names three big precious-metals royalty stocks. Here's how they stack up and what to check before you buy.
Aug 14, 2026
Franco-Nevada: What You Need to Know
Franco-Nevada is the largest precious-metals royalty company and the anchor of Porter Stansberry's Royalty Riches story. Here's how the model works.
Aug 14, 2026
Franco-Nevada Stock: What You Need to Know
Franco-Nevada (FNV) is the first name Porter Stansberry teases in Royalty Riches. Here's the reveal, the bull case, and the Cobre Panama risk.
Aug 14, 2026
Gold Royalty Stocks: What You Need to Know
Gold royalty stocks own a slice of mines without running them. Here are the three names in Porter Stansberry's Royalty Riches and how to weigh them.
Aug 14, 2026
Gold Streaming Stocks: What You Need to Know
Gold streaming stocks buy future production at a fixed low price. Here's how streaming differs from royalties and which names sit in Porter Stansberry's promo.
Aug 14, 2026
Oil Royalty Stocks: What You Need to Know
Oil royalty stocks own mineral rights and collect revenue from Permian operators. Here are the two names in Porter Stansberry's Royalty Riches.
Aug 14, 2026
Porter Stansberry Review: What You Need to Know
Porter Stansberry founded Porter & Co. and built a career on contrarian financial publishing. Here's the Royalty Riches thesis and what the offer costs.
Aug 14, 2026
RGLD Dividend: What You Need to Know
Royal Gold (RGLD) has raised its dividend for 25 straight years. Here's how the payout works, the profit-per-employee claim, and what to watch.
Aug 14, 2026
Royal Gold Stock: What You Need to Know
Royal Gold (RGLD) is one of Porter Stansberry's Royalty Riches picks. Here's the reveal, the 39-employee efficiency story, and what to watch.
Aug 14, 2026
Royalty Companies: What You Need to Know
Royalty companies own mineral rights and collect revenue without operating mines or wells. Here are the five names in Porter Stansberry's Royalty Riches.
Aug 14, 2026
Texas Pacific Land Stock: What You Need to Know
Texas Pacific Land (TPL) is the 'Accidental Oil Empire' in Porter Stansberry's Royalty Riches. Here's the reveal, the water business, and what to watch.
Aug 14, 2026
TPL Meaning: What You Need to Know
TPL is the ticker for Texas Pacific Land, the oil royalty name in Porter Stansberry's Royalty Riches. Here's what the symbol means and where it came from.
Aug 14, 2026
Triple Flag Precious Metals Stock: What You Need to Know
Triple Flag Precious Metals (TFPM) is the youngest pick in Porter Stansberry's Royalty Riches. Here's the reveal, the Elliott stake, and what to watch.
Aug 14, 2026
Viper Energy Stock: What You Need to Know
Viper Energy (VNOM) is the 'zero employee' oil royalty pick in Porter Stansberry's Royalty Riches. Here's the reveal, the dividend, and the caveat.
Aug 11, 2026
Porter & Co.'s 'Trump's New Silicon Dollar' — The Six Stocks Behind the AI Chokepoint Thesis
Porter Stansberry pitches a 'silicon dollar' replacing the petrodollar, with six chokepoint stocks. We analyze Vicor, Versamet, EQT, Viper Energy,
Aug 5, 2026
Porter & Co.'s 'Trump's Silicon Dollar' — The Six Chokepoint Stocks We Found
Porter Stansberry's latest promo argues the petrodollar is being replaced by a 'silicon dollar' backed by AI's physical inputs.